NEWS AROUND THE WORLD: Reflections on the Cost-Effectiveness of Recombinant FSH in Assisted Reproduction. The Clinician's Perspective
- 1 January 2001
- journal article
- research article
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 18 (2) , 45-55
- https://doi.org/10.1023/a:1026501821849
Abstract
Purpose: To analyze the relative cost-effectiveness of recombinant FSH (rFSH) and urinary FSH (uFSH) in assisted reproduction techniques (ART). Methods: Calculation of the average cost-effectiveness ratio and the incremental cost-effectiveness ratio to compare costs and effects (pregnancy rates) of the two therapeutic options (rFSH and uFSH). Results: Assuming that the cost of the procedure per ART cycle is between 100,000 pesetas (601 euro) and 150,000 pesetas (901.52 euro), and pricing the GnRH analogues used for pituitary suppression at 35,000 pesetas (210.3 euro), the cost-effectiveness ratio is better for rFSH than for uFSH, implying that the cost per pregnancy is lower when the recombinant preparation is used. Conclusions: In ART, the use of rFSH is more cost-effective than uFSH.Keywords
This publication has 25 references indexed in Scilit:
- Recombinant human FSH versus highly purified urinary FSH: a randomized study in intrauterine insemination with husbands' spermatozoaHuman Reproduction, 2000
- Intrauterine insemination or in-vitro fertilisation in idiopathic subfertility and male subfertility: a randomised trial and cost-effectiveness analysisThe Lancet, 2000
- Reducing the Risk of Multiple Births by Transfer of Two Embryos after in Vitro FertilizationNew England Journal of Medicine, 1998
- Recombinant follicle-stimulating hormone (FSH; Puregon) is more efficient than urinary FSH (Metrodin) in women with clomiphene citrate-resistant, normogonadotropic, chronic anovulation: a prospective, multicenter, assessor-blind, randomized, clinical trialFertility and Sterility, 1998
- Recombinant follicle-stimulating hormone (follitropin beta, Puregon) yields higher pregnancy rates in in vitro fertilization than urinary gonadotropinsFertility and Sterility, 1997
- Manipulation of Human Ovarian Function: Physiological Concepts and Clinical Consequences*Endocrine Reviews, 1997
- Immunology: Pregnancy and birth in an in-vitro fertilization cycle after controlled ovarian stimulation in a woman with a history of allergic reaction to human menopausal gonadotrophinHuman Reproduction, 1996
- Recombinant follicle stimulating hormone (rFSH; Puregon) in assisted reproduction: More oocytes, more pregnancies. Results from five comparative studiesHuman Reproduction Update, 1996
- In Vitro fertilization: A cost-effective alternative for infertile couples?Journal of Assisted Reproduction and Genetics, 1995
- The Cost of a Successful Delivery with in Vitro FertilizationNew England Journal of Medicine, 1994